Provided by Tiger Trade Technology Pte. Ltd.

MSA Safety

187.69
-1.2100-0.64%
Post-market: 187.690.00000.00%16:15 EDT
Volume:193.88K
Turnover:36.43M
Market Cap:7.24B
PE:23.34
High:190.74
Open:190.15
Low:186.81
Close:188.90
52wk High:208.92
52wk Low:151.11
Shares:38.58M
Float Shares:36.18M
Volume Ratio:0.88
T/O Rate:0.54%
Dividend:2.13
Dividend Rate:1.14%
EPS(TTM):8.04
EPS(LYR):7.09
ROE:23.66%
ROA:11.07%
PB:5.18
PE(LYR):26.47

Loading ...

MSA Safety Q1 Adjusted Earnings, Revenue Rise

MT Newswires Live
·
May 05

MSA Safety Q1 FY26 diluted EPS rises 21% to 1.83; net sales increase 10% to 464 million

Reuters
·
May 05

MSA Safety reports Q1 adjusted EPS $1.99, consensus $1.83

TIPRANKS
·
May 05

BRIEF-MSA Safety Q1 Adjusted EPS USD 1.99 Vs. IBES Estimate USD 1.83

Reuters
·
May 05

MSA Safety Q1 EPS USD 1.83

THOMSON REUTERS
·
May 05

MSA Safety Q1 Sales USD 463.6 Million VS. Ibes Estimate USD 451.3 Million

THOMSON REUTERS
·
May 05

MSA Safety Q1 Adjusted Net Income USD 77.5 Million VS. Ibes Estimate USD 72.8 Million

THOMSON REUTERS
·
May 05

MSA Safety Q1 Adjusted EPS USD 1.99 VS. Ibes Estimate USD 1.83

THOMSON REUTERS
·
May 05

MSA Safety Inc: Maintaining Mid-Single-Digit 2026 Organic Sales Growth Outlook

THOMSON REUTERS
·
May 05

BRIEF-Msa Safety Announces 56 Consecutive Years Of Annual Dividend Increases

Reuters
·
May 04

MSA Safety raises quarterly dividend to $0.54 per share

Reuters
·
May 04

MSA Safety Inc - Raises Qtrly Dividend to $0.54 per Common Share

THOMSON REUTERS
·
May 04

MSA Safety Announces 56 Consecutive Years of Annual Dividend Increases

THOMSON REUTERS
·
May 04

Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update

GlobeNewswire
·
Apr 30

Press Release: OBOOK Holdings Inc. Announces Financial Results for the Full Year 2025 Ended December 31, 2025

Dow Jones
·
Apr 30

Earning Preview: MSA Safety this quarter’s revenue is expected to increase by 12.09%, and institutional views are bullish

Earnings Agent
·
Apr 27

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

GlobeNewswire
·
Apr 23

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

GlobeNewswire
·
Apr 22

Alterity’s ATH434 Shows Phase 2 Efficacy Signal in MSA on New Composite Scale

TIPRANKS
·
Apr 22

MSA Safety showcases G1 XR SCBA at FDIC International

Reuters
·
Apr 21